



IAP6 Rec'd PCT/PTO 21 FEB 2006

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/540,718✓
	Filing Date	June 24, 2005
	First Named Inventor	Stewart Duncan
	Art Unit	Not Yet Assigned
Total Number of Pages in This Submission	Examiner Name	Not Yet Assigned
	Attorney Docket Number	3998-051954

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts Under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Post card Cited References
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	The Webb Law Firm		
Signature			
Printed Name	William H. Logsdon		
Date	February 16, 2006	Reg. No.	34,219

CERTIFICATE OF TRANSMISSION / MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Bruce L. White	Date	February 16, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2



Application No. 10/540,718
Paper dated February 16, 2006
Information Disclosure Statement
Attorney Docket No. 3998-051954

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/540,718
Applicants : Stewart Duncan et al.
Title : Methods of Diagnosing, Preventing, and Treating Early Onset of Pulmonary Hypertension
Filed : June 24, 2005
Priority Date : December 24, 2002
Examiner : Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the requirements of 37 CFR §§ 1.56, 1.97, and 1.98, the Applicants hereby submit this Information Disclosure Statement together with a completed Form PTO/SB/08A and one copy of the references listed thereon.

The references identified on Form PTO/SB/08A were identified by the Applicants and cited and discussed in the specification of the application.

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Alexandria, VA 22313-1450 on February 16, 2006

Bruce L. White

(Name of Person Mailing Paper or Fee)

Bruce L. White 02/16/06

Signature

Date

Application No. 10/540,718
Paper dated February 16, 2006
Information Disclosure Statement
Attorney Docket No. 3998-051954

Pursuant to 37 C.F.R. § 1.97(b)3, no fee is believed to be due for the submission of this Information Disclosure Statement, as it is being submitted before the mailing date of a first Office Action on the merits. Nevertheless, the Commissioner for Patents is hereby authorized to charge any fees which may be required to Deposit Account No. 23-0650. One (1) original and two (2) copies of this Information Disclosure Statement are enclosed.

Respectfully submitted,

THE WEBB LAW FIRM

By 

William H. Logsdon
Registration No. 22,132
Attorney for Applicants
700 Koppers Building
436 Seventh Avenue
Pittsburgh, Pennsylvania 15219-1845
Telephone: 412-471-8815
Facsimile: 412-471-4094
E-mail: webblaw@webblaw.com



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/540,718
				Filing Date	June 24, 2005
				First Named Inventor	STEWART, Duncan J.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	5	Attorney Docket Number	3998-051954

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US- 5,585,357	12-17-1996	Dolle et al.	
		US- 6,184,210	02-06-2001	Keana et al.	
		US- 6,245,523	06-12-2001	Altieri	
		US- 09/404,652	09-24-2001	Stewart	
		US- 2002/102576	08-01-2002	Machodo Rajiv et al.	
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		CA 2,227,425	09-27-1999	Angogen Inc.		
		WO 93/05071	03-18-1993	Immunex Corp		
		WO 96/03982	02-15-1996	Sanofi Winthrop Inc.		
		WO 97/06255	02-20-1997	Univ Ottawa		
		WO 97/26331	07-24-1997	Univ Ottawa		
		WO 97/32601	09-12-1997	Chugai Pharmaceutical Co. Ltd.		
		WO 98/02170	01-22-1998	Leuven Research and Dev.		
		WO 01/76457	10-18-2001	Cogent Neuroscience Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/540,718
				Filing Date	June 24, 2005
				First Named Inventor	STEWART, Duncan J.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	3998-051954
Sheet	2	of	5		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Babaei Saied et al., "Endothelial Cell Apoptosis and Microvascular Loss Represent Important Mechanisms of Monocrotaline (MCT)- Induced Pulmonary Hypertension in rats." Circulation, Vol. 108, no. 17 supplement, IV-270.	
		Bimbaum, M.J. et al., "An Apoptosis-Inhibiting Gene from a Nuclear Polyhedrosis Virus Encoding a Polypeptide with Cys/His Sequence Motifs", Virology (1994) 68:2521-2528	
		Boudreau, et al., "Suppression of ICE and Apoptosis in Mammary Epithelial Cells by Extracellular matrix", Science, 267:891, 1995.	
		Clem, R.J. et al., "Control of Programmed Cell Death by the Baculovirus Genes p35 and iap", Mol Cell Biol (1994) 14:5212-5222	
		Cohen et al., "Glucocorticoid Activation of a Calcium-Dependent Endonuclease in Thymocyte Nuclei Leads to Cell Death", 1984, J. Immunol., 132:38-42.	
		Cotter et al., "Micro-filament-disrupting Agents Prevent the Formation of Apoptotic Bodies in Tumor Cells Undergoing Apoptosis", 1992, Cancer Res., 52:997-1005.	
		Cowan, KN, "Complete Reversal of Fatal Pulmonary Hypertension in Rats by a Serine Elastase Inhibitor", Nat Med 6(6):698-702, 2000	
		Deng, Z. "Familial Primary Pulmonary Hypertension (Gene PPH1) is Caused by Mutations in the Bone Morphogenetic Protein Receptor - II Gene", J Hum Genet. 2000;67:737-744.	
		Duckett, C.S. et al., "A Conserved Family of Cellular Genes Related to the Baculovirus iap Gene and Encoding Apoptosis Inhibitors", EMBO J (1996) 15:2685-2694.	
		Duke et al., "Endogenous Endonuclease-Induced DNA Fragmentation: An Early Event in Cell-Mediated Cytolysis", 1983, Proc. Natl. Acad. Sci., U.S.A., 80:6361-6365.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/540,718
				Filing Date	June 24, 2005
				First Named Inventor	STEWART, Duncan J.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	3998-051954
Sheet	3	of	5		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Ellis et al., "Mechanisms and Functions of Cell Death", 1991, Annu. Rev. Cell. Biol, 7:663-698	
		Enari, et al., "Sequential Activation of ICE-Like and CPP32-Like Proteases During Fas-Mediated Apoptosis", Nature, 380:723, 1996.	
		Gotoh, N, "Apoptosis in Microvascular Endothelial Cells of Perfused Rabbit Lungs with Acute Hydrostatic Edema", J Appl Physiol 88(2):518-26, 2000.	
		Haffner, R. et al., "Biochemical Properties and Biological Effects of p53", Curr Op Gen Dev (1995) 5:84-90.	
		Hay, B.A. et al., "Drosophila Homologs of Baculovirus Inhibitor of Apoptosis Proteins Function to Block Cell Death", Cell (1995) 83:1253-1262.	
		Hockenberry, D. et al., "Ccl-2 is an Inner Mitochondrial Membrane Protein That Blocks Programmed Cell Death", Nature (1990) 379:349-353.	
		Jacobson et al., "Bcl-2 Blocks Apoptosis in Cells Lacking Mitochondrial DNA", 1993, Nature, 361:365-369.	
		Kroemer, G. et al., "The Biochemistry of Programmed Cell Death", FASEB J (1995) 9:1277-1287.	
		Liston, P. et al., "Suppression of Apoptosis in Mammalian Cells by NAIP and a Related Family of IAP Genes", Nature (1996) 379:349-353.	
		Martin, S.J. et al., "Protease Activation during Apoptosis: Death by a Thousand cuts?", Cell (1995) 82:349-352	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/540,718
				Filing Date	June 24, 2005
				First Named Inventor	STEWART, Duncan J.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	3998-051954
Sheet	4	of	5		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Morrell NW et al., "Altered Growth Response of Pulmonary Artery Smooth Muscle Cells...", 2001, Circulation.	
		Rabinovitch, M., "Pathobiology of Pulmonary Hypertension", Clin Chest Med 22(3):433-49, 2001.	
		Revesz et al., "Synthesis of P1 Aspartate-Based Peptide Acyloxymethyl and Fluoromethyl Ketones as Inhibitors of Interleukin-1B-Converting Enzyme", Tetrahedron Lett. 35, 9693-9696, 1994.	
		Rothe, M. et al., "The TNFR2-TRAF Signaling Complex Contains Two Novel Proteins Related to Baculoviral Inhibitor of Apoptosis Proteins", Cell (1995) 83:1243-1252.	
		Roy, N. et al., "The Gene for Neuronal Apoptosis Inhibitory Protein was Partially Deleted in Individuals with Spinal Muscular Atrophy", Cell (1995) 80:167-178.	
		Schlegel, et al., "CPP32/Apopain is a Key Interleukin 1B Converting Enzyme-like Protease Involved in Fas-Mediated Apoptosis", J. Biol. Chem., 271:1841, 1996.	
		Shi et al., "Role for C-Mycin Activation-Induced Apoptotic Cell Death in T Cell Hybridomas", 1992, Science, 257:212-215.	
		Tarasevicienne-Stewart Laimute et al., "Inhibition of the BGEF Receptor 2 Combined with Chronic Hypoxia Causes Cell Death-Dependent Pulmonary Endothelial Cell Proliferation and Severe Pulmonary Hypertension", FASEB Journal, Vol. 15, No. 2, Feb 2001, p. 427-438.	
		Telford et al., "Evaluation of Glucocorticoid-induced DNA Fragmentation in Mouse Thymocytes by Flow Cytometry" 1991, Cell Prolif., 24:447-459.	
		Tudor, RM et al., "The Pathology of Pulmonary Hypertension", Clin Chest Med 22(3):405-18, 200.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/540,718
				Filing Date	June 24, 2005
				First Named Inventor	STEWART, Duncan J.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Attorney Docket Number	3998-051954				
Sheet	5	of	5		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	.	Zhang S et al., "Bone Morphogenetic Proteins Induce Apoptosis in Human Pulmonary Vascular Smooth Muscle Cells", 2003 AJP.	
	.	The International PPH Consortium, "Heterozygous Germline Mutations in BMPR2, Encoding a TGF-B Receptor, Cause Familial Primary Pulmonary Hypertension", Nature Genetic, 26:81-84 (2000).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.